Has Binu John received payments from drug or device companies?

Yes. Drug and device makers reported $32,594 in general payments to Binu John across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Binu John did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Binu John come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Binu John

Gastroenterology · Richmond, VANPI 1790978187

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $27,543 of the $32,594 with a category attached, or 84.5%. 8 manufacturers reported payments, led by GSK at 37.7% of the total. Reporting peaked in 2022 at $14,769 and has fallen 50.4% since, to $7,323 in 2025. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,594in general payments, 2019–2025

Across 20 payments — averaging $1629.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$12K
Exelixis Inc.$6K
Ipsen Biopharmaceuticals, Inc$4K
Madrigal Pharmaceuticals$4K
Dova Pharmaceuticals$3K
AstraZeneca$2K
plus $2K from 2 others

$984,152in research payments, 2019–2025

Across 116 payments — averaging $8484.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Exelixis Inc.$330K
Takeda Pharmaceuticals U.S.A., Inc.$269K
GSK$215K
Genentech, Inc.$135K
E.r. Squibb & Sons, L.L.C.$32K
Bayer$3K

What the payments were for

Consulting fees$27,54385%
Speaking & faculty fees$3,21310%
Travel & lodging$1,0963%
Food & beverage$7422%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	3	$12,304
Exelixis Inc.	3	$5,601
Ipsen Biopharmaceuticals, Inc	3	$3,812
Madrigal Pharmaceuticals	5	$3,511
Dova Pharmaceuticals	1	$3,000
AstraZeneca	3	$2,465
Eisai Inc.	1	$1,875
Gilead	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Cabometyx$5,500
IQIRVO$3,812
REZDIFFRA$3,488
DOPTELET$3,000
IMFINZI$2,465
LENVIMA$1,875

How this compares

$32,594 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia →

Other gastroenterology in Richmond

Arun SanyalRichmond$855K
Michael FuchsRichmond$126K
Michael ManetasRichmond$125K
Jasmohan BajajRichmond$72K
Arthi SanjeeviRichmond$22K
Henry EllettRichmond$22K
Ray KeateRichmond$22K
Tilak ShahRichmond$20K
Joseph SpataroRichmond$19K
Richard SterlingRichmond$14K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →